Join +750K new investors every month who copy stock picks from billionaire's portfoliosSign Up Free

NeoGenomics expands I-O profiling test lineup

Published 06/02/2017, 09:35 AM
© Reuters.  NeoGenomics expands I-O profiling test lineup
MRK
-
NEO
-
  • Adjusting for recent advances in immunotherapy, NeoGenomics (NEO) expands its Immuno-Oncology profiling test menu. Specifically, its NeoTYPE cancer profiles now include Tumor Mutation Burden (TMB) and microsatellite instability (MSI) testing.
  • TMB is a new biomarker designed to predict response to PD-1 and PD-L1 checkpoint inhibitors (e.g., Merck (NYSE:MRK)'s KEYTRUDA and Bristol-Myers Squibb's OPDIVO).
  • MSI testing is being added after the FDA approved the use of KEYTRUDA in patients with MSI-high or mismatch repair deficient (MMR) solid tumors.
  • Now read: Biotech Forum Daily Digest: Headwinds Remain. Spotlight On MediWound


Original article

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.